Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Sotomayor

Allergy North Syracuse, NY Medical Doctor

NPI 1861461477 CMS profile 175588

5229 Witz Drive, North Syracuse, NY 13212

Open in the dashboard

General payments

$64,014

855 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juan Sotomayor of North Syracuse, NY is reported in the CMS Open Payments database as having received $64,014 across 855 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,754 173
2024 General $9,868 126
2023 General $11,547 136
2022 General $14,121 150
2021 General $2,065 97
2020 General $1,086 63
2019 General $13,574 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Sotomayor
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Juan Sotomayor were reported at $11,754. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Juan Sotomayor Allergy median Middle half National median
2019 $13,574 $506 $151–$1,337 $163
2020 $1,086 $409 $108–$1,162 $114
2021 $2,065 $549 $125–$1,485 $132
2022 $14,121 $666 $161–$1,594 $149
2023 $11,547 $780 $186–$1,916 $160
2024 $9,868 $1,031 $271–$2,196 $164
2025 $11,754 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $35,820 141 payments
  2. GlaxoSmithKline, LLC. $9,775 120 payments
  3. Pharming Healthcare, Inc. $4,286 15 payments
  4. Genzyme Corporation $3,164 117 payments
  5. Amgen Inc. $2,510 31 payments
  6. Novartis Pharmaceuticals Corporation $1,017 43 payments
  7. Pfizer Inc. $958 47 payments
  8. Regeneron Healthcare Solutions, Inc. $846 46 payments
  9. BioCryst US Sales Co., LLC $708 35 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $543 28 payments
  11. Other $4,385 232 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,290 19 payments
  2. Food and Beverage $18,962 821 payments
  3. Consulting Fee $6,500 1 payment
  4. Honoraria $3,000 1 payment
  5. Travel and Lodging $2,207 11 payments
  6. Education $54 2 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $34,018 66 payments
  2. NUCALA Respiratory $8,015 30 payments
  3. RUCONEST $4,286 15 payments
  4. DUPIXENT $4,076 163 payments
  5. TEZSPIRE Inflammation $2,470 28 payments
  6. FASENRA $1,464 32 payments
  7. NUCALA Immunology $1,170 54 payments
  8. Orladeyo $708 35 payments
  9. AIRSUPRA $686 13 payments
  10. BREZTRI $669 12 payments
  11. Other $10,470 548 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Allergy/ Immunology: 449

Drug cost

$8,720

Median for Allergy/ Immunology: $169,700

Branded share of claims

100%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $8,720

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$7,363 — —
DUPIXENT
$740 — —
XOLAIR
$356 — —
NUCALA
$338 — —
Orladeyo
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

855 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record